• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Relmada Therapeutics Inc (NQ: RLMD )

    3.400 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Relmada Therapeutics Inc

    < Previous 1 2 3 4 Next >
    Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Relmada Therapeutics: Q1 Earnings Insights
    Via Benzinga
    Relmada Therapeutics, Inc. (NASDAQ:RLMD) Investor Alert: Investigation Concerning Potential Securities Laws Violations
    San Diego, CA -- (SBWIRE) -- 05/11/2023 -- An investigation was announced for investors of Relmada Therapeutics, Inc. (NASDAQ:RLMD) shares over potential securities laws violations by Relmada... 
    Via SBWire
    Earnings Preview For Relmada Therapeutics
    Via Benzinga
    Preview: Relmada Therapeutics's Earnings
    Via Benzinga
    Relmada Shares Nosedive As Another Depression Trial Goes Up In Smoke
    Via Benzinga
    Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Relmada Therapeutics, Inc. (RLMD) Investigation
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Earnings Scheduled For May 11, 2023
    Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
    Via Benzinga
    RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    RLMD INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
    From The Rosen Law Firm, P.A.
    Via Business Wire
    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    Earnings Scheduled For March 23, 2023
    Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
    Via Benzinga
    Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
    In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major... 
    Via Benzinga
    Looking Into Relmada Therapeutics's Recent Short Interest
    Relmada Therapeutics's (NASDAQ:RLMD) short percent of float has fallen 13.6% since its last report. The company recently reported that it has 1.72 million shares sold short, which is 5.78% of all... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Aggressively Buying
    The Dow Jones closed higher by over 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Looking Into Relmada Therapeutics's Recent Short Interest
    Relmada Therapeutics's (NASDAQ:RLMD) short percent of float has fallen 8.99% since its last report. The company recently reported that it has 2.77 million shares sold short, which is 9.31% of all... 
    Via Benzinga
    S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
    U.S. stocks traded higher toward the end of trading, with the NASDAQ gaining around 100 points on Thursday. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
    Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split. 
    Via Benzinga
    Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher
    U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday. 
    Via Benzinga
    Dow Rises 150 Points; US Jobless Claims Increase To 230,000
    U.S. stocks traded higher this morning, with the Dow Jones gaining over 150 points on Thursday. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
      During Thursday's trading, 138 companies set new 52-week lows. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
      On Friday, 72 companies hit new 52-week lows. 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.